Array BioPharma Initiates Clinical Trials of Cancer Drug
Posted on: Friday, 4 May 2007, 12:00 CDT
Array BioPharma has initiated dosing cancer patients in a phase I clinical trial with ARRY-520, a targeted small molecule anticancer drug.
ARRY-520 is a potent kinesin spindle protein inhibitor that caused marked tumor regression in preclinical models of human cancer at tolerated doses, often leading to complete, durable responses.
The trial, which will be conducted in the US, is designed to evaluate the safety, tolerability and pharmacokinetics of ARRY-520 following intravenous administration to patients with advanced cancer. In addition, the trial will examine indicators of therapeutic activity in these patients.
Kevin Koch, president and chief scientific officer, said: "We are pleased that ARRY-520 has advanced to the stage of treated cancer patients in a phase I clinical trial. We are looking forward to continued progress on ARRY-520, as well as our other nine development programs, during 2007."
Source: Datamonitor
Related Articles
- Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial
- Array BioPharma Initiates Phase 1 Clinical Trial for Anticancer KSP Inhibitor ARRY-520
- Sunesis Pharmaceuticals Reports Positive Initial Results From Phase 2 Small Cell Lung Cancer Trial With SNS-595
- CTI Ends Key Lung Cancer Trial
- ZIOPHARM Announces Interim Results in ZIO-101 Phase I Solid Tumor Cancer Trial; Clinical Activity in Several Cancers
- Pro-Pharmaceuticals Retains Dr. James T. Gourzis to Provide Clinical Management & Strategic Development of Its Europe-Based Phase III Colorectal Cancer Trial
- Antigenics Updates Business Strategy and Outlines Timeline for the Analysis of Its Phase 3 Kidney Cancer Trial
- CyberKnife Center of Miami Seeks Patients for Prostate Cancer Trial
- Cancer Trial Starts
- Vitamin E Scare Hurts Cancer Trial; Doctors Say Their Study on Supplement, Prostate Cancer Prevention is Safe
 |
 |
User Comments (0)
RSS Feeds